Skip to main content
Premium Trial:

Request an Annual Quote

Avecia and TriLink to Integrate Technology

This article has been updated from a previous version to include additional information about the partnership.

NEW YORK, Feb. 27 (GenomeWeb News) - Avecia and TriLink announced today they will adopt common technology to offer customers "seamless" scale-up in oligo development and manufacturing.

 

Avecia is a GMP oligo manufacturer based in Millford, Mass., while TriLink, based in San Diego, is a custom oligonucleotide manufacturer with a focus on the discovery and pre-clinical stages of drug discovery.

 

The companies said that the alliance will speed the manufacture of oligos for drug discovery, development, and commercialization, and will offer an option for drugmakers "looking to minimize the challenges and risks associated with transitioning from a research-grade vendor to an oligonucleotide development service and manufacturing company."

 

Benefits of the common technology platform include "regulatory simplicity, cost control, time savings and risk minimization," the companies said.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.